Clinical trials: Recurrence Hepatocellular Carcinoma
HCC - Hepatocellular Carcinoma
A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
This study aims to explore the value of the 'HAIC Apatinib Camrelizumab' triple regimen for perioperative treatment of resectable hepatocellular carcinoma.
- Trial name
- NCT07618546
- Testing
- Camrelizumab (anti-PD-1 inhibitor), Apatinib Mesylate Tablets, FOLFOX-HAIC
- Volunteers
- 208 people
- Sponsor
- Henan Cancer Hospital
Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC)
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
The goal of this interventional clinical study is to learn the safety and preliminary efficacy of XH001 injection (Personalized mRNA tumor neoantigen vaccine) combined with standard adjuvant treatment in treating patients with…
- Conditions
- Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC), Hepatocellular Carcinoma (HCC), Gastric Cancer (GC)
- Trial name
- NCT07594964
- Testing
- XH001 Injection, mFOLFIRINOX Treatment Regimen
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Shenzhen Xinhe Biomedical
Liver Cancer
Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor.
- Trial name
- NCT00956930
- Testing
- yttrium Y 90 glass microspheres, Doxorubicin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Northwestern University
Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection…
- Trial name
- NCT05367687
- Testing
- Camrelizumab、Rivoceranib, Camrelizumab
- Where
- China
- Volunteers
- 251 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Resectable Hepatocellular Carcinoma
AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
This is a Phase 2, open-label, single-arm study of neoadjuvant immune-checkpoint blockade therapy (AK104) combining with TACE for resectable hepatocellular carcinoma.
- Trial name
- NCT05578430
- Testing
- Cadonilimab, TACE, Surgery
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
This phase II trial is to see if bevacizumab works in treating patients who have unresectable nonmetastatic liver cancer that has not spread to the main portal vein.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00055692
- Testing
- bevacizumab
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
This phase II trial is studying selumetinib to see how well it works in treating patients with locally advanced or metastatic liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00604721
- Testing
- selumetinib, pharmacological study
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Hepatitis C Virus Infection
Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
We conducted a randomized controlled trial of adjuvant interferon (IFN) therapy in patients with hepatitis-C virus (HCV)-related cirrhosis who underwent curative resection of hepatocellular carcinoma (HCC) to investigate whether…
- Conditions
- Hepatocellular Carcinoma, Hepatitis C Virus Infection, Liver Cirrhosis, Interferon Treatment
- Trial name
- NCT00273247
- Testing
- Interferon alpha-2b
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute, Milan
Male Breast Cancer, Recurrent Melanoma
Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
This pilot trial studies propranolol hydrochloride in treating patients with locally recurrent or metastatic solid tumors that cannot be removed by surgery.
- Conditions
- Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, Stage IV Melanoma
- Trial name
- NCT02013492
- Testing
- propranolol hydrochloride, Correlative Studies
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- William Carson
Radiofrequency Ablation, Carcinoma, Hepatocellular
RFA Using Combined Bipolar and Monopolar Energy Deliver With Twin Cooled-Wet Electrodes
In this study, a dual / Twin Cooled-wet electrode was used to perform RFA therapy on residual tumors after transarterial chemo-embolization and to find out the therapeutic results.
- Trial name
- NCT04331184
- Testing
- RFA using combined bipolar and monopolar energy deliver
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- Seoul National University Hospital
HCC
Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver Transplantation
To analyze the safety, efficacy and pharmacokinetic characteristics of sorafenib combined with compound huangdai tablets in patients with recurrent hepatocellular carcinoma after liver transplantation
- Trial name
- HCC (NCT04232722)
- Testing
- Arsenicals
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma
Hepatocellular Carcinoma Recurrence and Anesthesia
The investigators will verify the prognosis of hepatocellular carcinoma (HCC) according to the main anesthetic agents used for the general anesthesia.
- Trial name
- NCT02643173
- Testing
- Volatile anesthetics, Intravenous anesthetics
- Where
- South Korea
- Volunteers
- 259 people
- Sponsor
- Seoul National University Bundang Hospital
Hepatocellular Carcinoma, Liver Transplant; Complications
Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation
The use of devices for liver grafts perfusion before transplantation, either hypothermic (HOPE) or normothermic (NMP), is rapidly spreading thanks to the promising results obtained so far in terms of graft survival and…
- Trial name
- NCT06236568
- Testing
- D-HOPE machine perfusion, Liver transplantation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Hepatitis C, Hepatocellular Carcinoma
Direct Acting Antiviral-Post Authorization Safety Study
This is an independent optional sub-study parallel to TARGET-HCC (NCT02954094). The purpose of Direct-Acting Antiviral-Post Authorization Safety Study (DAA-PASS) is to investigate the impact of exposure to direct-acting…
- Trial name
- NCT03707080
- Where
- 62 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- Target PharmaSolutions, Inc.
Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery.
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Gallbladder Carcinoma
- Trial name
- NCT01425879
- Testing
- Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter
Clinical research of Yang Yin Fu Zheng Jie Du therapy in recurrence of Hepatocellular Carcinoma less than 3 cm in diameter.The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu…
- Trial name
- YYFZJDTRHCLT3D (NCT04264962)
- Testing
- Yang Yin Fu Zheng Jie Du therapy, Routine medical care
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Beijing Ditan Hospital
Carcinoma, Hepatocellular
Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT Patients
This study is to investigate the efficacy and safety of Folfox4 chemotherapy regimen to prevent early recurrence for hepatocellular carcinoma patients with portal vein tumor thrombus following curative resection
- Trial name
- NCT02813096
- Testing
- folfox4 chemotherapy regimen
- Volunteers
- 500 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma, Liver Cirrhoses
Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
Hepatocellular Carcinoma (HCC) is a major health concern in the United States, particularly among people with liver cirrhosis. Out of every 100 patients with liver cancer, only 18 will survive 5 years or more.
- Trial name
- NCT03219372
- Testing
- Pravastatin Pill
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Cedars-Sinai Medical Center
Recurrent Hepatocellular Carcinoma
A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation
Hepatocellular carcinoma (HCC) represent approximately 70-85% of liver cancer, in which Hepatitis B virus (HBV) is the major etiologic agent accounting for at least 80% of HCC in Asian countries.
- Trial name
- NCT03634683
- Testing
- LioCyx
- Where
- 3 sites in China, Singapore
- Sponsor
- Lion TCR Pte. Ltd.
Liver Carcinoma
Hepatocellular Carcinoma Treated With Iodine-125 Implantation
To prospectively evaluate whether use of combined radiofrequency ablation (RFA) and percutaneous iodine-125 (125I) seeds implantation results in better survival compared with use of RFA alone in patients with hepatocellular…
- Trial name
- NCT01717729
- Testing
- Radiofrequency Ablation, iodine
- Volunteers
- 136 people
- Sponsor
- The Second People's Hospital of GuangDong Province